Search results
Results from the WOW.Com Content Network
The combination of Rekambys and Vocabria injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/ml) with their current ARV treatment, and when the virus has not developed resistance to certain class of anti-HIV medicines called non-nucleoside reverse transcriptase ...
Immune reconstitution inflammatory syndrome (IRIS) is a condition seen in some cases of HIV/AIDS or immunosuppression, in which the immune system begins to recover, but then responds to a previously acquired opportunistic infection with an overwhelming inflammatory response that paradoxically makes the symptoms of infection worse.
The combination is indicated for the treatment of human immunodeficiency virus 1 (HIV 1) infection in people weighing at least 14 kilograms (31 lb) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. [6] [7]
Raltegravir (Isentress), developed by Merck & Co., was the first INSTI approved by the FDA in October 2007.; Elvitegravir (Vitekta), licensed by Gilead Sciences from Japan Tobacco, was approved by the U.S. Food and Drug Administration in August 2012, for use in adults starting HIV treatment for the first time as part of the fixed dose combination with emtricitabine and tenofovir disoproxil ...
Treatment as prevention rose to great prominence in 2011, as part of the HPTN 052 study, which shed light on the benefits of early treatment for HIV positive individuals. Evidence through observational, ecological and clinical trials reveal positive results in regards to the implementation of antiretroviral drugs as preventative measures ...
As of 2019, it is listed by the World Health Organization (WHO) as the first-line treatment for adults with HIV/AIDS, with tenofovir/lamivudine/efavirenz as an alternative. [2] It may be used in people with both HIV and tuberculosis , however if the person is on rifampicin a larger dose of dolutegravir is needed.
Following infection with HIV, the rate of clinical disease progression varies enormously between individuals. Many factors such as host susceptibility and immune function, [2] [3] [4] health care and co-infections, [5] [6] [7] as well as factors relating to the viral strain [8] [9] may affect the rate of clinical disease progression.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!